Request Copyright Permission

Inhaled Antibiotics: Negotiating the Obstacles to Treat Mycobacterial Lung Disease

Hofmann T, Banaschewski B, Stapleton KW, Kaiser K, Canisius S, Ufer S.

Respiratory Drug Delivery 2020. Volume 1, 2020: 25-34.


Mycobacterial lung diseases (MLD) are increasingly being recognized as a global health concern. Tuberculosis and nontuberculous mycobacterial pulmonary disease are difficult to treat infections, requiring extensive treatment durations of multiple systemic drugs. These regimens often lead to significant adverse drug events, without necessarily improving bacterial clearance. This review provides an overview of the difficulties in current treatment strategies of MLD, and the potential benefit of inhaled drug delivery in these treatments.

I have a subscription

Log in for instant access.

Forgotten Password?

I do not have a subscription

Purchase Article (in PDF format)

Ordering from RDD Online

Add To Cart $35

↑ Back to Top